Cipla’s generic Viread approved by the FDA
The Food and Drug Administration has approved Cipla’s generic Viread (tenofovir disoproxil fumarate) tablets. Cipla said it would begin shipping the drug immediately.
The drug is indicated to treat patients ages 12 years and older with HIV-1 in combination with other antiretroviral agents. Cipla’s generic Viread will be available in 300-mg dosage strength. The product had U.S. sales of roughly $725 million for the 12 months ended November 2017, according to IQVIA data.
The drug is indicated to treat patients ages 12 years and older with HIV-1 in combination with other antiretroviral agents. Cipla’s generic Viread will be available in 300-mg dosage strength. The product had U.S. sales of roughly $725 million for the 12 months ended November 2017, according to IQVIA data.